Anne Cathrine Staff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Cathrine Staff has a total of 376 co-authors. Here are the top co-authors by number of shared publications:
Meryam Sugulle
Division of Obstetrics and Gynaecology, Oslo University Hospital
14 shared publications- Meryam Sugulle
Division of Obstetrics and Gynaecology, Department of Obstetrics, Oslo University Hospital, Oslo, Norway; University of Oslo, Faculty of Medicine, Oslo, Norway
10 shared publications Ralf Dechend
Experimental and Clinical Research Center (Max-Delbrück Center for Molecular Medicine) and Medical Faculty of the Charité and Franz-Volhard Clinic, Helios-Klinikum, Helios Klinikum Berlin-Buch, Berlin, Germany
10 shared publications- Ralf Dechend
Experimental and Clinical Research Centre (ECRC), Max Delbrück Centre for Molecular Medicine, Berlin, Germany
7 shared publications - Björn Nordlund
Department of Women’s and Children’s Health, Karolinska Institutet, 171 77 Stockholm, Sweden
6 shared publications - Florian Herse
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
6 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Frontiers Media SA in Frontiers in Global Women's Health
- Vol. 7, 1889953
A mobile health-assisted cardiovascular follow-up after pregnancy complications (MumCare): protocol for a randomized controlled trial
Objective: A history of hypertensive disorders of pregnancy and/or gestational diabetes is associated with increased risk of long-term maternal cardiovascular (CV) disease. Despite recommendations for preventive strategies, few women receive CV follow-up postpartum. We have developed a personalized digital mobile Health companion, the MumCare (Mum’s cardiovascular health for life) application, aiming at improving control of modifiable risk factors for CV disease and to bridge hospital and community health services. This paper describes the protocol for a MumCare randomized controlled trial in Norway. Methods: Study participation is offered to women at Oslo University Hospital with a diagnosis of hypertensive disorders of pregnancy and/or gestational diabetes. Following informed consent (either during pregnancy or within 4 weeks postpartum), a block randomization process assigns participants to one of two groups (access to the Mum Care app or not). The app provides educational material, allows women to track modifiable risk factors, and prompts feedback to registered blood pressures. It also prompts the women to book the nationally recommended follow-up at their general practitioner’s at 3–4 and 12 months postpartum. The primary study objective is to assess the effect of MumCare application access on 1-year follow-up rate with a general practitioner. Secondary objectives are to assess group differences at 14 months postpartum regarding: 1) satisfaction with the postpartum mHealth-assisted technology, 2) self-management evaluation, general self-efficacy; and at 14–18 months: 3) modifiable risk factors for CV disease (including hypertension, dyslipidemia, blood sugar control, smoking, weight and physical activity), CV non-invasive hemodynamics and CV-related biomarkers. Discussion: This randomized controlled trial tests the effect of a mobile Health-assisted follow-up of modifiable risk factors after pregnancy complications associated with premature CV disease in women. A study limitation is a risk of underrepresentation of recently immigrated women due to the restricted language options offered in the app. Study protocols registration: NCT05835596.
- 13 October 2026
- Published by Frontiers Media SA in Frontiers in Global Women's Health
- Vol. 7, 1889953
Open AccessA mobile health-assisted cardiovascular follow-up after pregnancy complications (MumCare): protocol for a randomized controlled trial
Objective: A history of hypertensive disorders of pregnancy and/or gestational diabetes is associated with increased risk of long-term maternal cardiovascular (CV) disease. Despite recommendations for preventive strategies, few women receive CV follow-up postpartum. We have developed a personalized digital mobile Health companion, the MumCare (Mum’s cardiovascular health for life) application, aiming at improving control of modifiable risk factors for CV disease and to bridge hospital and community health services. This paper describes the protocol for a MumCare randomized controlled trial in Norway. Methods: Study participation is offered to women at Oslo University Hospital with a diagnosis of hypertensive disorders of pregnancy and/or gestational diabetes. Following informed consent (either during pregnancy or within 4 weeks postpartum), a block randomization process assigns participants to one of two groups (access to the Mum Care app or not). The app provides educational material, allows women to track modifiable risk factors, and prompts feedback to registered blood pressures. It also prompts the women to book the nationally recommended follow-up at their general practitioner’s at 3–4 and 12 months postpartum. The primary study objective is to assess the effect of MumCare application access on 1-year follow-up rate with a general practitioner. Secondary objectives are to assess group differences at 14 months postpartum regarding: 1) satisfaction with the postpartum mHealth-assisted technology, 2) self-management evaluation, general self-efficacy; and at 14–18 months: 3) modifiable risk factors for CV disease (including hypertension, dyslipidemia, blood sugar control, smoking, weight and physical activity), CV non-invasive hemodynamics and CV-related biomarkers. Discussion: This randomized controlled trial tests the effect of a mobile Health-assisted follow-up of modifiable risk factors after pregnancy complications associated with premature CV disease in women. A study limitation is a risk of underrepresentation of recently immigrated women due to the restricted language options offered in the app. Study protocols registration: NCT05835596.
- Open Access
- 21 August 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (9) , 1659-1673
Circulating Cardiovascular Biomarkers 1–3 Years Following Hypertensive Pregnancy Disorders: Associations With Postpartum Cardiovascular Structure and Function
Hypertensive disorders of pregnancy (HDP) confer increased cardiovascular disease (CVD) risk postpartum. Screening methods targeting women with increased risk are lacking, limiting personalized follow-up. Circulating biomarkers may assist CVD risk stratification. We aimed to assess whether circulating biomarkers were associated with measures of cardiovascular structure and function following HDP and normotensive pregnancies (controls). We examined 275 women 1–3 years postpartum (176 following HDP and 99 parous controls). Circulating biomarkers (hs-CRP, non-HDL cholesterol, glucose, eGFR, cTnT, NT-proBNP, GDF-15, sHLA-G, SAA1) and cardiovascular function and structure measures were examined [pulse wave velocity (PWV), carotid intima-media thickness (CIMT) and echocardiography]. Group differences were tested by Mann-Whitney U test and chi-square. Associations were assessed by univariate regression analyses. A p-value < 0.05 was considered statistically significant. Women following HDP displayed significantly higher rates of hypertension (5% vs. 0%) and metabolic syndrome (7% vs. 1%) than controls. Circulating biomarker levels were similar between study groups. In univariate regression analyses for the prior HDP group, non-HDL cholesterol was significantly associated with PWV and CIMT. Additionally, glucose and hs-CRP were significantly associated with PWV. These associations were not reproduced for controls, except for non-HDL cholesterol which was significantly associated with CIMT. In conclusion, women following HDP and normotensive pregnancies had similar postpartum levels of circulating biomarkers, but circulating biomarkers were significantly associated with measures of arterial stiffness (PWV and CIMT) in women with prior HDP. Our findings support current guidelines recommending CVD follow-up after HDP. Non-HDL cholesterol, glucose and hs-CRP may possibly help refining personalized cardiovascular follow-up postpartum. Graphical Abstract
- 21 August 2026
- Published by Springer Nature in Reproductive Sciences
- Vol. 33 (9) , 1659-1673
Open AccessCirculating Cardiovascular Biomarkers 1–3 Years Following Hypertensive Pregnancy Disorders: Associations With Postpartum Cardiovascular Structure and Function
Hypertensive disorders of pregnancy (HDP) confer increased cardiovascular disease (CVD) risk postpartum. Screening methods targeting women with increased risk are lacking, limiting personalized follow-up. Circulating biomarkers may assist CVD risk stratification. We aimed to assess whether circulating biomarkers were associated with measures of cardiovascular structure and function following HDP and normotensive pregnancies (controls). We examined 275 women 1–3 years postpartum (176 following HDP and 99 parous controls). Circulating biomarkers (hs-CRP, non-HDL cholesterol, glucose, eGFR, cTnT, NT-proBNP, GDF-15, sHLA-G, SAA1) and cardiovascular function and structure measures were examined [pulse wave velocity (PWV), carotid intima-media thickness (CIMT) and echocardiography]. Group differences were tested by Mann-Whitney U test and chi-square. Associations were assessed by univariate regression analyses. A p-value < 0.05 was considered statistically significant. Women following HDP displayed significantly higher rates of hypertension (5% vs. 0%) and metabolic syndrome (7% vs. 1%) than controls. Circulating biomarker levels were similar between study groups. In univariate regression analyses for the prior HDP group, non-HDL cholesterol was significantly associated with PWV and CIMT. Additionally, glucose and hs-CRP were significantly associated with PWV. These associations were not reproduced for controls, except for non-HDL cholesterol which was significantly associated with CIMT. In conclusion, women following HDP and normotensive pregnancies had similar postpartum levels of circulating biomarkers, but circulating biomarkers were significantly associated with measures of arterial stiffness (PWV and CIMT) in women with prior HDP. Our findings support current guidelines recommending CVD follow-up after HDP. Non-HDL cholesterol, glucose and hs-CRP may possibly help refining personalized cardiovascular follow-up postpartum. Graphical Abstract
- 22 May 2026
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 146 (7)
Når forløsning er eneste løsning, må bedre screening på plass
22.05.2026: Invitert kommentar - Innføringen av utvidet screening for preeklampsirisiko har latt vente på seg og er et eksempel på hvordan finansiering og organisering kan hindre forbedringer for gravide og nyfødte.
- 22 May 2026
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 146 (7)
Når forløsning er eneste løsning, må bedre screening på plass
22.05.2026: Invitert kommentar - Innføringen av utvidet screening for preeklampsirisiko har latt vente på seg og er et eksempel på hvordan finansiering og organisering kan hindre forbedringer for gravide og nyfødte.
- Open Access
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Global Women's Health
- Vol. 7, 1717203
Co-creation of a mobile health program (MumCare) for preventing maternal cardiovascular disease after pregnancy complications
Objective: Epidemiological studies show an increased risk for premature maternal cardiovascular disease in women after pregnancy complications, like preeclampsia, gestational hypertension and gestational diabetes mellitus. Our goal was to create a novel “digital companion” for women with such pregnancy complications, in the format of a mobile health-assisted user-centered follow-up software application (app). Methods: A cardiovascular postpartum follow-up program was developed as a digital companion, including a new mobile application (app), which is based on Norwegian obstetric and international guidelines. The MumCare app was developed through a co-creation process that included users, stakeholders, and clinical experts. Five qualitative interviews and 10 qualitative co-creative user testing interviews were conducted throughout the development stages to improve the perceived usefulness of the companion. The objective of the present study was to analyze the iterative co-creation process including users, stakeholders and clinical experts. Results: Phase 1 involved developing the companion within an interdisciplinary expert group through an iterative process in close dialogue with users. Explorative user interviews in Phase 2 ( n = 5) supported the translation of guidelines into a structured app format, visualized as MumCare sketches for design, functionality and user communication. During Phase 3, the app sketches were revised in collaboration with users, in application interviews ( n = 7). During Phase 4, the programmed prototype was refined through feedback from pilot users ( n = 3). The user groups highlighted several app benefits, including a follow-up system of personal modifiable risk factors, a user-friendly system for tracking blood pressure over time, with individualized feedback and prompts. The use of non-ambiguous language and symbols was appreciated among users, who also contributed new content items to the app. Conclusion: User-centered co-creation improved several important features during the companion development process. The MumCare app is being tested in a prospective randomized controlled clinical trial that started in June 2024. Clinical trial registration: Clinicaltrials.gov reg ., identifier NCT05835596.
- 30 April 2026
- Published by Frontiers Media SA in Frontiers in Global Women's Health
- Vol. 7, 1717203
Open AccessCo-creation of a mobile health program (MumCare) for preventing maternal cardiovascular disease after pregnancy complications
Objective: Epidemiological studies show an increased risk for premature maternal cardiovascular disease in women after pregnancy complications, like preeclampsia, gestational hypertension and gestational diabetes mellitus. Our goal was to create a novel “digital companion” for women with such pregnancy complications, in the format of a mobile health-assisted user-centered follow-up software application (app). Methods: A cardiovascular postpartum follow-up program was developed as a digital companion, including a new mobile application (app), which is based on Norwegian obstetric and international guidelines. The MumCare app was developed through a co-creation process that included users, stakeholders, and clinical experts. Five qualitative interviews and 10 qualitative co-creative user testing interviews were conducted throughout the development stages to improve the perceived usefulness of the companion. The objective of the present study was to analyze the iterative co-creation process including users, stakeholders and clinical experts. Results: Phase 1 involved developing the companion within an interdisciplinary expert group through an iterative process in close dialogue with users. Explorative user interviews in Phase 2 ( n = 5) supported the translation of guidelines into a structured app format, visualized as MumCare sketches for design, functionality and user communication. During Phase 3, the app sketches were revised in collaboration with users, in application interviews ( n = 7). During Phase 4, the programmed prototype was refined through feedback from pilot users ( n = 3). The user groups highlighted several app benefits, including a follow-up system of personal modifiable risk factors, a user-friendly system for tracking blood pressure over time, with individualized feedback and prompts. The use of non-ambiguous language and symbols was appreciated among users, who also contributed new content items to the app. Conclusion: User-centered co-creation improved several important features during the companion development process. The MumCare app is being tested in a prospective randomized controlled clinical trial that started in June 2024. Clinical trial registration: Clinicaltrials.gov reg ., identifier NCT05835596.
- Open Access
- 22 April 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101474
Self-reported primary preventive follow-up of women’s cardiovascular health after hypertensive pregnancy complications and gestational diabetes
- 22 April 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101474
Open AccessSelf-reported primary preventive follow-up of women’s cardiovascular health after hypertensive pregnancy complications and gestational diabetes
- Open Access
- 3 April 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101466
Physical activity and cardiovascular risk factors after hypertensive pregnancy complications
- 3 April 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 44, 101466
Open AccessPhysical activity and cardiovascular risk factors after hypertensive pregnancy complications
- Top Cited PapersOpen Access
- 27 January 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (1)
Hypertensive disorders of pregnancy: The use of eHealth technologies in postpartum follow-up strategies to reduce cardiovascular risk – A scoping review
Objective: Women with prior hypertensive disorders of pregnancy (HDP) have increased risk of developing future cardiovascular disease. The objective of this scoping review was to map the literature regarding the use of eHealth measures in cardiovascular follow-up after HDP and identify research gaps. Methods: A systematic search was conducted in four databases. Primary research articles and guidelines were included. Abstract screening, full-text assessment and data extraction was performed to summarize the findings. Results: The search identified 4830 articles and 12 guidelines. Eleven publications and one guideline were included in the analyses. Various eHealth interventions were assessed, such as remote blood pressure monitoring, physical activity and weight management, with follow-up time from 6 weeks to 4 years. eHealth interventions targeting blood pressure and physical activity showed statistically significant positive effects. Conclusion: The scoping review identified eHealth interventions for cardiovascular follow-up after HDP that may empower women to optimize their cardiovascular health.
- 27 January 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (1)
Top Cited PapersOpen AccessHypertensive disorders of pregnancy: The use of eHealth technologies in postpartum follow-up strategies to reduce cardiovascular risk – A scoping review
Objective: Women with prior hypertensive disorders of pregnancy (HDP) have increased risk of developing future cardiovascular disease. The objective of this scoping review was to map the literature regarding the use of eHealth measures in cardiovascular follow-up after HDP and identify research gaps. Methods: A systematic search was conducted in four databases. Primary research articles and guidelines were included. Abstract screening, full-text assessment and data extraction was performed to summarize the findings. Results: The search identified 4830 articles and 12 guidelines. Eleven publications and one guideline were included in the analyses. Various eHealth interventions were assessed, such as remote blood pressure monitoring, physical activity and weight management, with follow-up time from 6 weeks to 4 years. eHealth interventions targeting blood pressure and physical activity showed statistically significant positive effects. Conclusion: The scoping review identified eHealth interventions for cardiovascular follow-up after HDP that may empower women to optimize their cardiovascular health.
- Open Access
- 10 December 2025
- Published by Elsevier in Pregnancy Hypertension
- Vol. 43, 101404
Cardiovascular phenotype in women 1–3 years after hypertensive pregnancy disorders: Impact of sex-independent and pregnancy-specific risk factors
- 10 December 2025
- Published by Elsevier in Pregnancy Hypertension
- Vol. 43, 101404
Open AccessCardiovascular phenotype in women 1–3 years after hypertensive pregnancy disorders: Impact of sex-independent and pregnancy-specific risk factors
- Open Access
- 24 October 2025
- Published by Wiley in Advanced Science
- Vol. 12 (48) , e14969
Identifying Key Questions and Challenges in Microchimerism Biology
Microchimerism research has recently gained renewed attention despite known existence of these rare cells for decades. Fetal and maternal microchimeric‐derived cells may have functional capabilities, and are increasingly associated with both beneficial and adverse health outcomes. Yet, establishing the role of microchimerism in health has been largely constrained methodologically and theoretically. The Microchimerism, Human Health, and Evolution Project address these challenges by calling on 29 leading microchimerism experts to put forth key research questions that can substantially advance the field. Seven major categories are identified: function and mechanism; microchimerism in interventions, treatment, and transplant; mapping “generational microchimerism”; evolution; microchimerism detection; appropriate experimental model systems; and definition of microchimerism. Identifying these questions ‐ and continuing to find answers ‐ will be crucial for advancing the knowledge of microchimerism in health and disease.
- 24 October 2025
- Published by Wiley in Advanced Science
- Vol. 12 (48) , e14969
Open AccessIdentifying Key Questions and Challenges in Microchimerism Biology
Microchimerism research has recently gained renewed attention despite known existence of these rare cells for decades. Fetal and maternal microchimeric‐derived cells may have functional capabilities, and are increasingly associated with both beneficial and adverse health outcomes. Yet, establishing the role of microchimerism in health has been largely constrained methodologically and theoretically. The Microchimerism, Human Health, and Evolution Project address these challenges by calling on 29 leading microchimerism experts to put forth key research questions that can substantially advance the field. Seven major categories are identified: function and mechanism; microchimerism in interventions, treatment, and transplant; mapping “generational microchimerism”; evolution; microchimerism detection; appropriate experimental model systems; and definition of microchimerism. Identifying these questions ‐ and continuing to find answers ‐ will be crucial for advancing the knowledge of microchimerism in health and disease.
- Open Access
- 15 October 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (2) , 550-569
Predelivery maternal circulating neutrophil extracellular traps and deoxyribonuclease in placental dysfunction and preeclampsia
- 15 October 2025
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 234 (2) , 550-569
Open AccessPredelivery maternal circulating neutrophil extracellular traps and deoxyribonuclease in placental dysfunction and preeclampsia